https://www.patientcareonline.com/view/abelacimab-receives-fast-track-designation-from-fda-for-prevention-of-stroke-systemic-embolism-in-patients-with-atrial-fibrillation
0
0
9/10/22 at 7:41am
Organization
Patientcareonline.com
Author
Sydney Jennings
Abelacimab is a dual-acting, fully human monoclonal antibody that selectively targets both factor XI and factor XIa with high affinity.
Create an account
or login to join the discussion